These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
To own FIGS, you need to believe it can turn its premium healthcare apparel brand and growing international presence into sustained, profitable growth. The latest earnings beat and 52 week high strengthen the near term growth catalyst around international expansion and Olympics related exposure, but they do not remove the key risk that elevated tariffs and expansion spending could squeeze margins if demand disappoints.
The recent extension of FIGS’ partnership to outfit Team USA medical staff through the 2028 Games ties directly into the current Olympics marketing focus that BTIG highlighted. This visibility, alongside new product innovations like its FIBREx fabric, reinforces the growth story around brand reach and product differentiation, even as investors weigh the risks of rising competition and execution challenges in new markets.
Yet investors should also be aware that tariff pressures and expansion driven inventory risk could still...
Read the full narrative on FIGS (it's free!)
FIGS’ narrative projects $656.8 million revenue and $37.0 million earnings by 2028.
Uncover how FIGS' forecasts yield a $9.52 fair value, a 22% downside to its current price.
Five Simply Wall St Community fair value estimates for FIGS span roughly US$4 to US$9.53 per share, underscoring how far apart individual views can be. Some focus on the recent earnings beat and Olympics linked brand exposure as potential supports for future performance, which makes it especially important to compare several of these perspectives side by side.
Explore 5 other fair value estimates on FIGS - why the stock might be worth as much as $9.52!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com